Literature DB >> 18840727

Platelet count in essential thrombocythemia: the more the better?

Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18840727      PMCID： PMC2569189          DOI： 10.1182/blood-2008-07-168807

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Federica Delaini; Vittoria Guerini; Marco Ruggeri; Francesco Rodeghiero; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

2.  Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?

Authors:  Ayalew Tefferi; Naseema Gangat; Alexandra P Wolanskyj
Journal:  Blood       Date:  2006-10-01       Impact factor: 22.113

3.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

Review 4.  Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Authors:  Tiziano Barbui; Giovanni Barosi; Alberto Grossi; Luigi Gugliotta; Lucio N Liberato; Monia Marchetti; Maria Gabriella Mazzucconi; Francesco Rodeghiero; Sante Tura
Journal:  Haematologica       Date:  2004-02       Impact factor: 9.941

5.  Acquired von Willebrand's disease in the myeloproliferative syndrome.

Authors:  U Budde; G Schaefer; N Mueller; H Egli; J Dent; Z Ruggeri; T Zimmerman
Journal:  Blood       Date:  1984-11       Impact factor: 22.113
  5 in total
  2 in total

1.  A pilot study of subcutaneous decitabine in β-thalassemia intermedia.

Authors:  Nancy F Olivieri; Yogen Saunthararajah; Vivek Thayalasuthan; Janet Kwiatkowski; Russell E Ware; Frans A Kuypers; Hae-Young Kim; Felicia L Trachtenberg; Elliott P Vichinsky
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

2.  Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Authors:  Robert Molokie; Donald Lavelle; Michel Gowhari; Michael Pacini; Lani Krauz; Johara Hassan; Vinzon Ibanez; Maria A Ruiz; Kwok Peng Ng; Philip Woost; Tomas Radivoyevitch; Daisy Pacelli; Sherry Fada; Matthew Rump; Matthew Hsieh; John F Tisdale; James Jacobberger; Mitch Phelps; James Douglas Engel; Santhosh Saraf; Lewis L Hsu; Victor Gordeuk; Joseph DeSimone; Yogen Saunthararajah
Journal:  PLoS Med       Date:  2017-09-07       Impact factor: 11.069
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.